Skip to main content

Reducing financial toxicity in bladder cancer care.

Publication ,  Journal Article
Kurnot, JA; Kaye, DR
Published in: Current opinion in urology
November 2024

Financial toxicity is a significant concern for many individuals with bladder cancer, which is, overall, the most expensive malignancy, per patient. Financial toxicity, defined as the harmful effects of treatment costs on an individual's quality of life, is associated with worse outcomes and decreased quality of life. Awareness of the objective and subjective factors that contribute to financial toxicity, and ways to mitigate their effects on patients, is essential to reduce the burden of bladder cancer care. This commentary aims to discuss the elements contributing to financial toxicity amongst bladder cancer patients, identify at-risk populations, and review current and potential strategies for mitigating financial burden.Bladder cancer is becoming more expensive as the use of novel therapies increases. Early data suggest how some of these novel treatments or changes in treatment delivery may impact costs. Potential innovative strategies for cost reduction include blue light cystoscopy, intravesical gemcitabine-docetaxel rather than BCG for high-risk nonmuscle-invasive patients, home BCG therapy, and surveillance guideline optimization. However, there is still much work to be done on the potential impacts of these treatment on financial toxicity. While there is a paucity of data on treatment changes to reduce financial toxicity, and cost data can be hard to access, clinicians can still reduce the financial burden of cancer care. Awareness, financial toxicity screening, cost communication, and/or early referral to financial navigators or other similar resources have the potential to reduce financial burden. Despite mounting evidence, these tools/techniques are largely underutilized.Many individuals with bladder cancer face significant financial toxicity, with the potential for this to worsen in the setting of rising treatment costs. Novel diagnostic and treatment modifications may reduce financial toxicity. However, awareness, screening, cost discussions, and utilization of financial navigators are tools/techniques that are currently available and should be used to reduce financial burden.

Duke Scholars

Published In

Current opinion in urology

DOI

EISSN

1473-6586

ISSN

0963-0643

Publication Date

November 2024

Volume

34

Issue

6

Start / End Page

484 / 488

Related Subject Headings

  • Urology & Nephrology
  • Urinary Bladder Neoplasms
  • Quality of Life
  • Humans
  • Health Care Costs
  • Cost of Illness
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kurnot, J. A., & Kaye, D. R. (2024). Reducing financial toxicity in bladder cancer care. Current Opinion in Urology, 34(6), 484–488. https://doi.org/10.1097/mou.0000000000001218
Kurnot, Jeremy A., and Deborah R. Kaye. “Reducing financial toxicity in bladder cancer care.Current Opinion in Urology 34, no. 6 (November 2024): 484–88. https://doi.org/10.1097/mou.0000000000001218.
Kurnot JA, Kaye DR. Reducing financial toxicity in bladder cancer care. Current opinion in urology. 2024 Nov;34(6):484–8.
Kurnot, Jeremy A., and Deborah R. Kaye. “Reducing financial toxicity in bladder cancer care.Current Opinion in Urology, vol. 34, no. 6, Nov. 2024, pp. 484–88. Epmc, doi:10.1097/mou.0000000000001218.
Kurnot JA, Kaye DR. Reducing financial toxicity in bladder cancer care. Current opinion in urology. 2024 Nov;34(6):484–488.

Published In

Current opinion in urology

DOI

EISSN

1473-6586

ISSN

0963-0643

Publication Date

November 2024

Volume

34

Issue

6

Start / End Page

484 / 488

Related Subject Headings

  • Urology & Nephrology
  • Urinary Bladder Neoplasms
  • Quality of Life
  • Humans
  • Health Care Costs
  • Cost of Illness
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services